Literature DB >> 18992745

RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F.

Moritz Leppkes1, Christoph Becker, Ivaylo I Ivanov, Sebastian Hirth, Stefan Wirtz, Clemens Neufert, Sandrine Pouly, Andrew J Murphy, David M Valenzuela, George D Yancopoulos, Burkhard Becher, Dan R Littman, Markus F Neurath.   

Abstract

BACKGROUND AND AIMS: IL-17-producing CD4(+) T-helper cells (Th17) contribute to chronic autoimmune inflammation in the brain, and levels of Th17-derived cytokines increase in patients with colitis, suggesting a role in pathogenesis. We analyzed the roles of Th17 cells and the transcription factor retinoic acid receptor-related organ receptor (ROR)gamma, which regulates Th17 differentiation, in chronic intestinal inflammation.
METHODS: Using an adoptive transfer model of colitis, we compared the colitogenic potential of wild-type, interleukin-17A (IL-17A)-, IL-17F-, IL-22-, and RORgamma-deficient CD4(+)CD25(-) T cells in RAG1-null mice.
RESULTS: Adoptive transfer of IL-17A-, IL-17F-, or IL-22-deficient T lymphocytes into RAG1-null mice caused severe colitis that was indistinguishable from that caused by wild-type cells. In contrast, transfer of RORgamma-null T cells failed to increase mucosal IL-17 cytokine levels and did not induce colitis. Treatment with IL-17A was able to restore colitis after transfer of RORgamma-null T cells, indicating a crucial role for Th17 cells in pathogenesis. Treatment of RAG1 mice that received IL-17F-null (but not wild-type) T cells with a neutralizing anti-IL-17A antibody significantly suppressed disease, indicating redundant biological effects of IL-17A and IL-17F.
CONCLUSIONS: We have identified a crucial role of RORgamma-expressing Th17 cells in chronic intestinal inflammation. RORgamma controls IL-17A and IL-17F production, and these cytokines have a redundant but highly pathogenic role in gut inflammation. Reagents that target RORgamma or a combination of anti-IL-17A and anti-IL-17F might be developed as therapeutics for chronic colitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992745     DOI: 10.1053/j.gastro.2008.10.018

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  181 in total

Review 1.  Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.

Authors:  Peter J Morrison; Sarah J Ballantyne; Marika C Kullberg
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

2.  The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.

Authors:  Mohamed El-Behi; Bogoljub Ciric; Hong Dai; Yaping Yan; Melissa Cullimore; Farinaz Safavi; Guang-Xian Zhang; Bonnie N Dittel; Abdolmohamad Rostami
Journal:  Nat Immunol       Date:  2011-04-24       Impact factor: 25.606

Review 3.  Animal models of IBD: linkage to human disease.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Curr Opin Pharmacol       Date:  2010-06-08       Impact factor: 5.547

4.  Potentiation of Th17 cytokines in aging process contributes to the development of colitis.

Authors:  Xinshou Ouyang; Zhuoshun Yang; Ruihua Zhang; Paul Arnaboldi; Geming Lu; Qingshan Li; Weidong Wang; Biao Zhang; Miao Cui; Huafeng Zhang; Jane Liang-Chen; Lihui Qin; Feng Zheng; Bo Huang; Huabao Xiong
Journal:  Cell Immunol       Date:  2010-10-27       Impact factor: 4.868

5.  T-bet expression by Th cells promotes type 1 inflammation but is dispensable for colitis.

Authors:  J Zimmermann; A A Kühl; M Weber; J R Grün; J Löffler; C Haftmann; R Riedel; P Maschmeyer; K Lehmann; K Westendorf; M-F Mashreghi; M Löhning; M Mack; A Radbruch; H D Chang
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

6.  Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.

Authors:  Leon P McLean; Raymond K Cross; Terez Shea-Donohue
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 7.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

8.  The Th17-defining transcription factor RORγt promotes glomerulonephritis.

Authors:  Oliver M Steinmetz; Shaun A Summers; Poh-Yi Gan; Timothy Semple; Stephen R Holdsworth; A Richard Kitching
Journal:  J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 10.121

9.  The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.

Authors:  T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

10.  Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis.

Authors:  Lie Di; Shekhar Srivastava; Olga Zhdanova; Yi Ding; Zhai Li; Heike Wulff; Maria Lafaille; Edward Y Skolnik
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.